Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta‐analyses
Open Access
- 1 July 2019
- journal article
- review article
- Published by Wiley in Developmental Neurobiology
- Vol. 79 (7), 684-698
- https://doi.org/10.1002/dneu.22715
Abstract
Individuals with Down syndrome (DS) are at high risk of developing Alzheimer's disease (AD). Discovering reliable biomarkers which could facilitate early AD diagnosis and be used to predict/monitor disease course would be extremely valuable. To examine if analytes in blood related to amyloid plaques may constitute such biomarkers, we conducted meta-analyses of studies comparing plasma amyloid beta (A beta) levels between DS individuals and controls, and between DS individuals with and without dementia. PubMed, Embase, and Google Scholar were searched for studies investigating the relationship between A beta plasma concentrations and dementia in DS and 10 studies collectively comprising >1,600 adults, including >1,400 individuals with DS, were included. RevMan 5.3 was used to perform meta-analyses. Meta-analyses showed higher plasma A beta(40) (SMD = 1.79, 95% CI [1.14, 2.44], Z = 5.40, p < .00001) and plasma A beta(42) levels (SMD = 1.41, 95% CI [1.15, 1.68], Z = 10.46, p < .00001) in DS individuals than controls, and revealed that DS individuals with dementia had higher plasma A beta(40) levels (SMD = 0.23, 95% CI [0.05, 0.41], Z = 2.54, p = .01) and lower A beta(42)/A beta(40) ratios (SMD = -0.33, 95% CI [-0.63, -0.03], Z = 2.15, p = .03) than DS individuals without dementia. Our results indicate that plasma A beta(40) levels may constitute a promising biomarker for predicting dementia status in individuals with DS. Further investigations using new ultra-sensitive assays are required to obtain more reliable results and to investigate to what extent these results may be generalizable beyond the DS population.Keywords
Funding Information
- Medical Research Council (MR/S011277/1)
- Wellcome Trust (098330/Z/12/Z)
- National Institute for Health Research
This publication has 79 references indexed in Scilit:
- Change in plasma Aβ peptides and onset of dementia in adults with Down syndromeNeurology, 2010
- An Overview of APP Processing Enzymes and ProductsNeuroMolecular Medicine, 2009
- The Relationship of Plasma Aβ Levels to Dementia in Aging Individuals With Down SyndromeAlzheimer Disease & Associated Disorders, 2009
- Plasma β‐amyloid and duration of Alzheimer's disease in adults with Down syndromeInternational Journal of Geriatric Psychiatry, 2009
- Plasma levels of nitric oxide related amino acids in demented subjects with Down syndrome are related to neopterin concentrationsAmino Acids, 2009
- Elevated Plasma β-Amyloid Peptide Aβ42 Levels, Incident Dementia, and Mortality in Down SyndromeArchives of Neurology, 2007
- Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degenerationEuropean Journal of Neuroscience, 2007
- Gene expression variation in Down's syndrome mice allows prioritization of candidate genesGenome Biology, 2007
- Epidemiology of Down syndromeMental Retardation and Developmental Disabilities Research Reviews, 2007
- Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.Proceedings of the National Academy of Sciences of the United States of America, 1993